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Abstract
Background: Concurrent severe carotid and cardiac disease is a challenging situation where 
staged surgery is probably the most common strategy. However, in patients with an unstable 
clinical presentation, the best approach is still a matter of debate. The aim of the study was to 
report in-hospital and midterm outcome in patients who received carotid artery stenting and 
synchronous cardiac surgery.
Methods: From June 1998 to July 2012, 54 consecutive patients who were treated at a high-
-volume university medical center with this hybrid approach were included in the study. All of 
the patients received carotid angioplasty while being administered aspirin and regular unfra-
ctionated heparin. Then, all of the patients were immediately transferred to the operating room 
for coronary and/or cardiac valve surgery. All of the patients were administered aspirin and 
clopidogrel once bleeding was ruled out, after surgery.
Results: There were 5 in-hospital surgical related deaths, and no patient suffered a stroke or 
required carotid urgent re-intervention. At follow-up (55 ± 28 months; range 1–144 months), 
there were no new neurological deficits, while one additional death occurred.
Conclusions: In this series, synchronous carotid stenting and cardiac surgery were feasible 
with an acceptable complication rate in a high-surgical-risk population, which could not un-
dergo staged procedures. (Cardiol J 2015; 22, 1: 25–30)
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Introduction
Periprocedural stroke remains an infrequent 
but catastrophic complication for open heart surgery 
(OHS) [1]. Patients with carotid and coronary artery 
disease are at higher risk for stroke during coronary 
artery bypass grafting (CABG), with a potential be-
nefit for those with previous carotid revascularization 
[2, 3]. For stable patients, staged revascularization 
(carotid and then CABG) seems to be the adequate 
strategy. However, in unstable patients, the best 
strategy is still under debate. Although there are few 
comparative studies between carotid endarterectomy 
(CEA) and carotid artery stenting (CAS) previous to 
cardiac surgery [4], some of them showed the safety 
and efficacy of CAS in high risk patients [5–7].
The objective of this study is to report the 
clinical outcomes of patients who received simul-
taneous CAS and open heart surgery.
Methods
Between June 1998 and July 2013, 692 conse-
cutive patients received CAS; 54 (7.8%) of them 
also received a simultaneous OHS immediately 
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Clinical and procedural data were collected in 
a database for all patients and clinical and echo-
-Doppler follow-up was carried out for outpatients.
All patients were hospitalized due to an acute 
coronary syndrome and/or cardiac failure due to 
coronary artery disease (CAD) and/or valvular 
disease. All patients were unstable despite com-
plete medical treatment and all of them were con-
sidered being at high surgical risk for the Heart 
Team. Their condition prevents the performing of 
the standard staged procedures approach, which 
is the most common strategy used in our hospital.
Patients with CAD cannot also be candidates 
for percutaneous coronary interventions. In case 
of valvular heart disease this should also be proven 
impossible to be solved by balloon valvuloplasty 
or other endovascular procedures when available.
CAS patients were diagnosed by echo-Doppler 
screening, and angiography was performed in all 
patients with severe lesions before therapeutic 
procedures.
An intervention was indicated in cases of se-
vere stenosis; ≥ 70% in symptomatic patients and 
≥ 80% in asymptomatic using the NASCET study 
method for measurements. All CAS stents were 
implanted using cerebral protection devices (CPD) 
after approval in January 1999.
All patients were taking aspirin 200 mg da-
ily; after arterial sheath insertion 10,000 IU of 
unfractionated heparin (UFH) was given to main-
tain an activated clotting time higher than 240 s. 
Immediately after stenting, under UFH effect, 
patients were transferred from the Cath Lab to the 
operating room for cardiac surgery intervention. 
Clopidogrel was started with a loading dose when 
bleeding was ruled out; usually 6–8 h after surgery.
In patients requiring prolonged mechanical 
ventilation, clopidogrel was given through the 
nasogastric tube.
Dual antiplatelet therapy was suggested for at 
least 1 month and oral anticoagulation according to 
cardiovascular surgery.
Angiographic success was defined as < 30% 
residual stenosis after stent implantation and clinic 
success when angiographic success was achieved wit-
hout a 30-day major complication (stroke, death, acute 
myocardial infarction [AMI], and/or urgent surgery).
All patients were evaluated by an indepen-
dent neurologist before and after CAS and a new 
computed tomography scan was obtained in cases 
presenting new symptoms or neurological compli-
cation after procedures.
Minor stroke was defined when a new neurolo-
gical deficit after procedures was ≤ 4 points on the 
NIH Stroke Scale at the independent neurologist 
evaluation; major stroke when the deficit was ≥ 4 
and transient ischemic attack (TIA) when a neu-
rological deficit was fully recovered within 24 h.
Neurological deficits were considered related 
to CAS when they occurred during CAS at any lo-
cation or the ipsilateral events when they occurred 
after cardiac surgery, and they were related to sur-
gery when contralateral to the stent and occurring 
after cardiac surgery.
Mortality was considered any death within 
30 days after index procedures. AMI was defined 
as either a new Q-wave or creatinine kinase-MB 
elevation (new Q-waves on ECG, ST elevation, 
or new left bundle branch block post CABG, CK-
-MB over 80 IU/mL, new wall motion changes by 
echocardiography).
A 30-day combined end point was defined as: 
all-cause death, AMI, urgent carotid surgery, TIA 
or any stroke.
CAS were performed by femoral access in the 
majority of patients and only in a few cases by radial 
approach at the very end of the series. The OHS 
was performed according to the regular practice 
of the surgical team under general anesthesia and 
extracorporeal circulation and myocardial protec-
tion. The CAS and OHS techniques were left to 
the operators’ discretion.
All patients signed their informed consents 
and accepted clinical follow-up.
Statistical analysis
Absolute numbers and percentages were used 
to describe the patients’ population. Continuous 
variables are shown as mean and standard devia-
tion. SPSS 11.0. was used for the analysis.
Results
This is a single center consecutive series of 
patients treated between June 1998 and July 2013 
who were included in the study.
Population characteristics are the following: 
mean age of 70.2 ± 8 years, 43 patients were male, 
15 diabetic, 6 had severe bilateral carotid steno-
sis, 29 severe lesions of the left main coronary 
artery, 19 severe left ventricular dysfunction (left 
ventricular ejection fraction < 30%), 10 previous 
myocardial infarction, and 6 previous cardiac sur-
gery (1 patient had 2 prior operations) (Table 1).
The standard EuroSCORE was 11.8 ± 2.8, 
Parssonet 14.4 ± 5, Society of Thoracic Surgeons 
(STS) for complications 26.2 ± 9, for stroke 2.7 ± 1.3, 
for STS death 3.7 ± 0.9 (Table 2). All patients were 
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unstable with a cardiac condition requiring urgent 
cardiac surgery and thus a previous carotid revascu-
larization which was performed simultaneously.
CAS and cardiovascular surgery
CAS was performed by a femoral approach in 
48 patients, by radial in 4, and humeral in 2. CPD 
were used in 53; 1 patient at the beginning of the 
series was treated without CPD. Self-expandable 
stents were used in all cases.
Four patients at the beginning of the series 
received bilateral CAS in the same setting. Angio-
graphic success was obtained in all cases.
After CAS, 27 patients received CABG alone, 
23 CABG plus aortic valve replacement (AVR), 
and 4 cases only valvular replacement (2 aortic; 
1 mitral and 1 mitral plus tricuspid).
Clinical success was achieved in 49 (90.7%) 
patients. Five patients died after surgery (4 had 
received combined surgery CABG plus AVR and 
1 only CABG for the second re-operation). One 
death was due to surgical bleeding (a patient with 
2 previous cardiovascular surgeries), 1 because 
a cardiogenic shock, and 3 due to multiorgan failure 
(Table 3).
No patient had neurological complications at 
30 days.
Follow-up
The follow-up was achieved in all cases at 
55 ± 28 (1–144) months, no patient suffered from 
neurological events, or any carotid or cardiova-
scular re-interventions. One patient died due to 
a non-related death (cancer).
Discussion
The association between carotid artery disease 
and CAD is a relatively frequent clinical presenta-
tion of vascular disease. About 22% of the referred 
patients for CABG had moderate to severe carotid 
artery stenosis while 30% of the referred for CEA 
had concomitant CAD [1].
While stroke is a devastating cardiac surgery 
complication and represents a challenge for car-
diovascular surgeons, it is well known that carotid 
artery disease increases neurological complication 
risks for those patients undergoing CABG; these 
complications can be fatal and non-fatal stroke, TIA 
and hypoxic encephalopathy causing important 
physical and psychological damage to patients and 
their families and also increasing hospital costs. 
Moreover, the risk of neurological complication 
becomes relevant with aging patients who are 
referred for OHS.
In a paper from Roach et al. [8] it was repor-
ted that 6.1% of patients had a neurological deficit 
immediately after CABG and the mortality rate 
of these patients was 21%. Thus stroke is also 
a condition which increases mortality rate after OHS.
Simultaneous CEA and CABG showed redu-
cing neurological complication but increasing the 
mortality rate and non-fatal AMI [9]. In a study 
from Rome University, which included 180 con-
secutives patients (1991–2002) that were treated 
with simultaneous CEA and surgery, the mortality 
rate was 10.1%, but in patients with EuroSCORE 
≥ 6 it was 14.5%. In this setting, we thought that 
Table 1. Clinical characteristics.
Age 70.3 ± 8
≥ 80 years 5 (9.3%)
Male 43 (79.6%)
Hypertension 50 (92.6%)
Diabetes mellitus 15 (27.8%)
Smokers 25 (46.3%)
Dyslipidemia 32 (59.3%)
Previous myocardial infarction 10 (18.5%)
Previous CABG* 6 (11.1%)
Previous transient ischemic attack 2 (3.7%)
Previous stroke 2 (3.7%)
Contralateral carotid occlusion 6 (11.1%)
Left ventricular ejection fraction ≤ 30 15 (27.8%)
*One patient had 2 previous coronary artery bypass graftings (CABG)
Table 3. 30-day outcomes.
Major stroke –
Minor stroke –
Transient ischemic attack –
Related to carotid artery stent death –
Related to cardiovascular surgery death 5 (9.2%)
Acute myocardial infarction 1 (1.8%)
Bleeding requiring reoperation 7 (13%)
Hemodialysis 5 (9.2%)
Table 2. Risk score.
Parssonet 14.4 ± 5
EuroSCORE 11.8 ± 2.8
STS complications 26.2 ± 9
STS stroke 2.7 ± 1.3
STS death 3.7 ± 0.9 
STS — Society of Thoracic Surgeons
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CAS currently represents one option with a lower 
risk for AMI in comparison to CEA.
Other report from Levy et al. [10], who used a 
simultaneous approach combining CEA and CABG 
in 80 patients, had the following perioperative 
outcomes: mortality rate 3.7%, stroke 2.5%, myo-
cardial infarction 3.7%. Combined complications 
of death + myocardial infarction + stroke was 
10%. However, CAS has shown a low myocardial 
infarction rate as complication leading to a lower 
long-term mortality rate [11].
In a recent publication from Shishehbor et al. 
[12], the authors analized 350 patients who recei-
ved 3 different strategies: staged CEA and OHS 
(n = 45), combined CAE plus OHS (n = 195) and 
staged CAS plus OHS (n = 110). The time between 
CEA and OHS was as soon as possible according 
to clinical condition, while for CAS and OHS it was 
4 weeks and 5 additional days after clopidogrel was 
stopped. The primary composite end point was 
all-cause death, stroke, and myocardial infarction. 
Staged CAS-OHS patients had more previous stro-
ke and underwent more complex surgery.
Regarding the outcomes; staged CAS-OHS and 
combined CEA-OHS had similar early outcomes, 
while staged CEA-OHS had more inter-stage myo-
cardial infarction. Subsequently, staged CAS-OHS 
experienced significantly fewer late hazard phase 
events in comparison to both staged CEA-OHS 
(adjusted hazard ratio [HR] 0.33; 95% confidence 
interval [CI] 0.15–0.77; p = 0.01) and combined 
CEA-OHS (adjusted HR 0.35; 95% CI 0.18–0.70; 
p = 0.003). Thus the outcomes are significantly 
in favor of staged CAS-OHS after the first year. 
Thirty days and one year death and stroke rates 
were similar but CAS group had a lower myocardial 
infarction rate and better evolution [12].
CAS and CEA have shown similar outcomes 
in high surgical risk patients. However, there are 
few studies comparing these 2 revascularization 
strategies for patients with severe CAD who need 
urgent CABG or valvular surgery. Moreover, there 
are some reports that have shown the feasibility 
and safety of staged CAS and CABG [13, 14]. But, 
unstable patients requiring an urgent OHS, who 
also have a severe carotid artery disease, represent 
an extremely high risk subgroup of patients, where 
a combined approach with a less invasive strategy, 
like CAS, to solve carotid artery stenosis which can 
increase stroke risk for OHS, with a simultaneous 
cardiovascular surgery, may reduce the global risk 
of both procedures appearing as an appealing stra-
tegy for patients with aggressive atherosclerotic 
disease manifestation [15].
In this present study, the hybrid, simulta-
neous (or synchronous) strategy (CAS and OHS) 
was feasible with a high but acceptable mortality 
rate (9.2%) considering such a high surgical risk 
population without suffering from neurological 
complications. This is very encouraging for this 
highly selective group of patients who could not be 
staged, which would be the best strategy.
In a multicenter study; the SHARP study: 101 
patients were treated with CAS and OHS and had 
a mortality and stroke rate of 2% [15]. This low 
mortality rate in comparison with our series can 
be explained by a different patient selection (our 
patients have a higher EuroSCORE [11.8 ± 2.8] 
than in SHARP study [8.6 ± 2.5]). This is also 
a more recent multicenter registry than our series; 
thus, the learning curve and technical advances 
would have had an impact on the clinical outcomes.
In addition, only 14% of patients in the SHARP 
study underwent valvular surgery, while 50% of 
our cases received combined CABG plus valvular 
replacement and 10% only valvular surgery; 2 si-
tuations which increased the mortality risk.
New procedures and strategies like new ge-
neration drug eluting stent [16–18] and new data 
supporting their use in complex anatomical and 
clinical scenarios, and percutaneous AVR [19, 20], 
endovascular mitral valve repair may change the 
outlook for some of these patients, who can be 
safely treated with minimally invasive procedures.
Although the long-term results of FREEDOM 
[21] and SYNTAX trials [22] clearly show that 
multivessel disease, mainly for those with diabetes 
mellitus and high Syntax Score, is still better tre-
ated with CABG; in our series, 20 of our patients 
required combined CABG plus AVR representing 
a higher surgical risk impossible to be compared 
with patients included in such trials.
However, for those unstable and/or very el-
derly patients with valvular and/or CAD, whenever 
possible, the percutaneous approach appears as 
a an alternative that allows for deferring the carotid 
revascularization if indicated.
Although in the present study CAS outcomes 
were quite similar to our stable series of patients 
and many other similar publications, we consi-
der that dual antiplatelet therapy represents an 
important part of the complexity of this challen-
ging clinical situation and; although CAS were 
performed only under aspirin and UFH, second 
antiplatelet drug (usually clopidogrel) should 
be started sooner after bleeding has been ruled 
out in order to prevent potential carotid stent 
thrombosis.
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Aspirin withdrawal before OHS may decrease 
risk of bleeding, but this strategy still remains 
controversial because it would increase the risk 
of coronary events and inflammatory response. 
However, in our strategy, aspirin was kept be-
cause dual antiplatelet therapy with clopidogrel 
or prasugrel has been related to a higher surgical 
related bleeding risk and we considered it too 
risky to implant a carotid artery stent without any 
antiplatelet therapy to prevent stent thrombosis 
before full dual antiplatelet therapy. The role of 
ticagrelor which decreased complication for those 
patients who received CABG in PLATO study must 
be further investigated for this potential indication 
in this group of patients [23–27].
Like all other CAS patients, the cases with 
a hybrid approach require strict blood pressure 
monitoring to prevent hypotension, a main factor to 
drive to stent thrombosis and hypertension which 
may drive to the hypoperfusion syndrome.
At the beginning of our series, 4 patients recei-
ved bilateral CAS without complication; however, 
after several publications and expert opinions about 
that situation describing that it may lead to a high risk 
of hypoperfusion syndrome [28, 29], we abandoned 
this strategy and in the cases with bilateral severe 
carotid artery stenosis we only treated the more 
severe one before cardiac surgery, and the other was 
left to the physician’s decision at follow-up.
Limitations of the study
This study has several limitations, such as: a sin-
gle center study without a control group, with a long 
period of recruitment because patients who cannot 
be staged are uncommon and their frequency seems 
to be decreasing as minimally invasive strategies 
are improving and becoming safer and effective. Ho-
wever, this is a consecutive series of patients where 
we used a strategy that is not so new and is still not 
widely accepted due to the lack of strong evidence.
Conclusions
This single center series showed that one sta-
ge hybrid strategy (CAS and simultaneous OHS) is 
a feasible and safe option for unstable high surgical 
risk patients with concomitant severe carotid and 
coronary and/or cardiac valvular disease requiring 
cardiovascular surgery that cannot be staged.
Conflict of interest: None declared
References
1. Naylor AR, Mehta Z, Rothwell PM, Bell PR. Carotid artery 
disease and stroke during coronary artery bypass: A critical re-
view of the literature. Eur J Vasc Endovasc Surgery, 2002; 23: 
283–294.
2. Fareed KR, Rothwell PM, Mehta Z, Naylor AR. Synchronous 
carotid endarterectomy and off-pump coronary bypass: An upda-
ted, systematic review of early outcomes. Eur J Vasc Endovasc 
Surgery, 2009; 37: 375–378.
3. Hirotani T, Kameda T, Kumamoto T, Shirota S, Yamano M. Stroke 
after coronary artery bypass grafting in patients with cerebrova-
scular disease. Ann Thoracic Surgery, 2000; 70: 1571–1576.
4. Ziada KM, Yadav JS, Mukherjee D et al. Comparison of results 
of carotid stenting followed by open heart surgery versus com-
bined carotid endarterectomy and open heart surgery (coronary 
bypass with or without another procedure). Am J Cardiol, 2005; 
96: 519–523.
5. Fairman R, Gray WA, Scicli AP et al. The capture registry: Analy-
sis of strokes resulting from carotid artery stenting in the post 
approval setting: Timing, location, severity, and type. Ann Surg, 
2007; 246: 551–556; discussion 556–558.
6. Gray WA, Hopkins LN, Yadav S et al. Protected carotid stenting 
in high-surgical-risk patients: The archer results. J Vascular Sur-
gery, 2006; 44: 258–268.
7. Yadav JS, Wholey MH, Kuntz RE et al. Protected carotid-artery 
stenting versus endarterectomy in high-risk patients. New Engl 
J Med, 2004; 351: 1493–1501.
8. Roach GW, Kanchuger M, Mangano CM et al. Adverse cerebral 
outcomes after coronary bypass surgery. Multicenter study of 
perioperative ischemia research group and the ischemia research 
and education foundation investigators. New Engl J Med, 1996; 
335: 1857–1863.
9. Naylor AR, Mehta Z, Rothwell PM, Bell PR. Reprinted article 
“carotid artery disease and stroke during coronary artery bypass: 
A critical review of the literature”. Eur J Vasc Endovas Surgery, 
2011; 42 (suppl. 1): S73–S83.
10. Levy E, Yakubovitch D, Rudis E et al. The role of combined 
carotid endarterectomy and coronary artery bypass grafting in 
the era of carotid stenting in view of long-term results. Interact 
Cardiovasc Thorac Surg, 2012; 15: 984–988. 
11. Roffi M, Cremonesi A. Current concepts on the management 
of concomitant carotid and coronary disease. J Cardiovasc Surg 
(Torino), 2013; 54: 47–54.
12. Shishehbor MH, Venkatachalam S, Sun Zet al. A direct compari-
son of early and late outcomes with three approaches to carotid 
revascularization and open heart surgery. J Am Coll Cardiol, 2013; 
62: 1948–1956.
13. Van der Heyden J, Suttorp MJ, Bal ET et al. Staged carotid angio-
plasty and stenting followed by cardiac surgery in patients with 
severe asymptomatic carotid artery stenosis: Early and long-term 
results. Circulation, 2007; 116: 2036–2042.
14. Guzman LA, Costa MA, Angiolillo DJ et al.A systematic review 
of outcomes in patients with staged carotid artery stenting 
and coronary artery bypass graft surgery. Stroke, 2008; 39: 
361–365.
www.cardiologyjournal.org 29
Oskar A. Mendiz et al., Hybrid strategy for carotid and cardiac disease
15. Versaci F, Reimers B, Del Giudice C et al. Simultaneous hybrid 
revascularization by carotid stenting and coronary artery bypass 
grafting: The sharp study. J Am Coll Cardiol, 2009; 2: 393–401.
16. Brugaletta S, Garcia-Garcia HM, Onuma Y, Serruys PW. Everolimus-
eluting absorb bioresorbable vascular scaffold: Present and future 
perspectives. Expert Review Medical Devices, 2012; 9: 327–338.
17. Garg S, Serruys P, Onuma Y et al. 3-year clinical follow-up of 
the xience v everolimus-eluting coronary stent system in the 
treatment of patients with de novo coronary artery lesions: The 
spirit ii trial (clinical evaluation of the xience v everolimus eluting 
coronary stent system in the treatment of patients with de novo 
native coronary artery lesions). J Am Coll Cardiol Cardiovascular 
Interventions, 2009; 2: 1190–1198.
18. Silber S, Windecker S, Vranckx P, Serruys PW. Unrestricted ran-
domised use of two new generation drug-eluting coronary stents: 
2-year patient-related versus stent-related outcomes from the 
resolute all comers trial. Lancet, 2011; 377: 1241–1247.
19. Kodali SK, Williams MR, Smith CR et al. Two-year outcomes af-
ter transcatheter or surgical aortic-valve replacement. New Engl 
J Med, 2012; 366: 1686–1695.
20. Makkar RR, Fontana GP, Jilaihawi H et al. Transcatheter aortic 
valve replacement for inoperable severe aortic stenosis. New 
Engl J Med, 2012; 366: 1696–1704.
21. Farkouh ME, Domanski M, Sleeper LA et al. Strategies for multi-
vessel revascularization in patients with diabetes. N Engl J Med, 
2012; 367: 2375–2384.
22. Serruys PW, Morice MC, Kappetein AP et al. SYNTAX Investi-
gators. Percutaneous coronary intervention versus coronary 
artery bypass grafting for severe coronary artery disease. N Engl 
J Med, 2009; 360: 961–972. Erratum in: N Engl J Med, 2013; 
368: 584.
23. Berg K, Langaas M, Ericsson M et al. Acetylsalicylic acid treat-
ment until surgery reduces oxidative stress and inflammation 
in patients undergoing coronary artery bypass grafting. Eur 
J Cardiothorac Surg, 2013; 43: 1154–1163. 
24. Miceli A, Duggan SM, Aresu G et al. Combined clopidogrel and 
aspirin treatment up to surgery increases the risk of postoperative 
myocardial infarction, blood loss and reoperation for bleeding 
in patients undergoing coronary artery bypass grafting. Eur 
J Cardiothorac Surg, 2013; 43: 722–728. 
25. Cannon CP, Harrington RA, James S et al.; PLATelet inhibition 
and patient Outcomes. Comparison of ticagrelor with clopidogrel 
in patients with a planned invasive strategy for acute coronary 
syndromes (PLATO): A randomised double-blind study investiga-
tors. Lancet, 2010; 375: 283–293.
26. Montalescot G, Wiviott SD, Braunwald E et al. Prasugrel 
compared with clopidogrel in patients undergoing percutane-
ous coronary intervention for ST-elevation myocardial in-
farction (TRITON-TIMI 38): Double-blind, randomised con-
trolled trial. TRITON-TIMI 38 Investigators. Lancet, 2009; 
373: 723–731. 
27. Becker RC, Bassand JP, Budaj A et al. Bleeding complications 
with the P2Y12 receptor antagonists clopidogrel and ticagrelor in 
the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur 
Heart J, 2011; 32: 2933–2944. 
28. Henry M, Gopalakrishnan L, Rajagopal S, Rath PC, Henry I, 
Hugel M. Bilateral carotid angioplasty and stenting. Catheteriza-
tion Cardiovasc Interventions, 2005; 64: 275–282.
29. Meyers PM, Higashida RT, Phatouros CC et al. Cerebral hyper-
perfusion syndrome after percutaneous transluminal stenting of 
the craniocervical arteries. Neurosurgery, 2000; 47: 335–343; 
discussion 343–335.
30 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 1
